Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, which is deemed compliant with the relevant regulations of the Major Asset Restructuring Management Measures for Listed Companies [1][2]. Group 1 - The restructuring meets the requirements of Article 11 of the Major Asset Restructuring Management Measures, ensuring that the asset valuation is fair and does not harm the legitimate rights and interests of the company and its shareholders [1]. - The company confirms that there are no legal obstacles to the transfer of assets prior to the transaction, and it does not involve the handling of related debts and liabilities [1]. - The company will maintain independence in personnel, assets, finance, institutions, and business after the restructuring, in accordance with the relevant regulations of the China Securities Regulatory Commission [1]. Group 2 - The restructuring complies with Article 43 of the Major Asset Restructuring Management Measures, ensuring that there are no ongoing investigations or violations of laws that could affect the transaction [2]. - The transaction is expected to enhance the quality of the company's assets and strengthen its ongoing operational capabilities without causing significant adverse changes to its financial status [2]. - The company will ensure that the transaction can be completed within the agreed timeframe, provided that all legal procedures and prerequisites are appropriately fulfilled [2]. Group 3 - The restructuring aligns with Article 44 of the Major Asset Restructuring Management Measures, promoting a diversified product matrix and preventing significant adverse impacts from competition or unfair related transactions [2].
迈普医学: 关于本次交易符合《上市公司重大资产重组管理办法》第十一条、第四十三条及第四十四条规定的说明